0001105806-17-000005.txt : 20170214
0001105806-17-000005.hdr.sgml : 20170214
20170213190525
ACCESSION NUMBER: 0001105806-17-000005
CONFORMED SUBMISSION TYPE: SC 13G/A
PUBLIC DOCUMENT COUNT: 1
FILED AS OF DATE: 20170214
DATE AS OF CHANGE: 20170213
SUBJECT COMPANY:
COMPANY DATA:
COMPANY CONFORMED NAME: Cidara Therapeutics, Inc.
CENTRAL INDEX KEY: 0001610618
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 461537286
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: SC 13G/A
SEC ACT: 1934 Act
SEC FILE NUMBER: 005-88806
FILM NUMBER: 17601588
BUSINESS ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 858-752-6170
MAIL ADDRESS:
STREET 1: 6310 NANCY RIDGE DRIVE
STREET 2: SUITE 101
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: K2 THERAPEUTICS, INC.
DATE OF NAME CHANGE: 20140611
FILED BY:
COMPANY DATA:
COMPANY CONFORMED NAME: LYTTON LAURENCE W
CENTRAL INDEX KEY: 0001105806
FILING VALUES:
FORM TYPE: SC 13G/A
MAIL ADDRESS:
STREET 1: 467 CPW
CITY: NY
STATE: NY
ZIP: 10025
SC 13G/A
1
cdtx.txt
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment 1)
(Name of Issuer) Cidara Therapeutics, Inc
(Title of Class of Securities) Common Stock
(CUSIP Number) 71757107
(Date of Event Which Requires Filing of this Statement) December 31, 2016
Check the appropriate box to designate the rule pursuant to which this
Schedule is filed:
[ ]Rule 13d-1(b)
[ X ]Rule 13d-1(c)
[ ]Rule 13d-1(d)
CUSIP No. 71757107
1.Names of Reporting Persons.
Laurence W.Lytton
2. Check the Appropriate Box if a Member of a Group (See Instructions)
a)..........................................................................
(b)..........................................................................
3.SEC Use Only
4.Citizenship or Place of Organization
USA
5.Sole Voting Power 553,475
6.Shared Voting Power 41,120
7.Sole Dispositive Power 553,475
8.Shared Dispositive Power 41,120
9.Aggregate Amount Beneficially Owned by Each Reporting
Person 594,595
10.Check if the Aggregate Amount in Row (9) Excludes Certain Shares
(See Instructions).................................
11.Percent of Class Represented by Amount in Row (9)
3.6%
12.Type of Reporting Person (See Instructions)
IN
Item 1.
(a)Name of Issuer Cidara Therapeutics, Inc
(b)Address of Issuer's Principal Executive Offices
6310 Nancy Ridge Drive
San Diego, CA 92121
Item 2.
(a)Name of Person Filing Laurence W. Lytton
(b)Address of Principal Business Office or, if none, Residence
467 CPW
New York, NY 10025
(c)Citizenship USA
(d)Title of Class of Securities Common
(e)CUSIP Number 71757107
Item 3. not applicable
Item 4.Ownership.
(a)Amount beneficially owned: 594,595 shares consisting of
508,852 shares held by the reporting person, 32,525 held in
the AWL Family LLC, 3,955 held in the IKL Trust, 9,893 held
in the KLL Family Trust, 17,772 held in the WWL Family Trust,
9,528 held in the Lytton-Kambara Foundation and 12,070 shares
held in other related accounts.
(b)Percent of class: 3.6%
(c)Number of shares as to which the person has:
(i)Sole power to vote or to direct the vote 553,475.
(ii)Shared power to vote or to direct the vote 41,120
(iii)Sole power to dispose or to direct the disposition of 553,475.
(iv)Shared power to dispose or to direct the disposition of 41,120
Item 5.Ownership of Five Percent or Less of a Class:
If this statement is being filed to report the fact that as of the
date hereof the reporting person has ceased to be the beneficial
owner of more than 5 percent of the class of securities, check the
following (X).
Item 6.Ownership of More than Five Percent on Behalf of Another Person.
Not applicable
Item 7.Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent Holding Company
Not applicable
Item 8.Identification and Classification of Members of the Group
Not applicable
Item 9.Notice of Dissolution of Group
Not applicable
Item 10.Certification
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held
for the purpose of or with the effect of changing or influencing the control
of the issuer of the securities and were not acquired and are not held
in connection with or as a participant in any transaction having that
purpose or effect.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete
and correct.
__02/13/17____________________________
Date
____s/ Laurence W. Lytton____________________________
Signature
_____Laurence W. Lytton___________________________
Name/Title